View Filing Data

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2024	Mar. 31, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-39126
Entity Registrant Name	CNS Pharmaceuticals, Inc.
Entity Central Index Key	0001729427
Entity Tax Identification Number	82-2318545
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2100 West Loop South
Entity Address, Address Line Two	Suite 900
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77027
City Area Code	800
Local Phone Number	946-9185
Title of 12(b) Security	Common Stock
Trading Symbol	CNSP
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Public Float			$ 8,780,000
Entity Common Stock, Shares Outstanding		2,944,381
Documents Incorporated by Reference [Text Block]	Portions of this registrant’s definitive proxy statement for its 2024 Annual Meeting of Stockholders to be filed with the SEC no later than 120 days after the end of the registrant’s fiscal year are incorporated herein by reference in Part III of this Annual Report on Form 10-K.
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	206
Auditor Name	MaloneBailey, LLP
Auditor Location	Houston, Texas

Equity (Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of stock option activity

Schedule of stock option activity
	Options		Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		51	$	168,547.02
Granted		106		4,460.14
Exercised		–		–
Forfeited		–		–
Expired		–		–
Outstanding, December 31, 2023		157		56,287.36
Granted		113		645.88
Exercised		–		–
Forfeited		–		–
Expired		–		–
Outstanding, December 31, 2024		270	$	33,000.37
Exercisable, December 31, 2024		175	$	48,148.42

Schedule of black-scholes option assumptions


	Year Ended	Year Ended
	December 31, 2024	December 31, 2023
Fair value of common stock on measurement date	$632.50 to $646.50 per share	$1.00 to $2.40 per share
Risk free interest rate (1)	3.80% to 4.39%	3.38% to 4.37%
Volatility (2)	102.25% to 118.36%	114.13% to 118.09%
Dividend yield (3)	0%	0%
Expected term (in years)	5.5 – 6.3	5.5 – 6.3

(1)	The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
(2)	The trading volatility was determined by calculating the volatility of the Company’s peer group.
(3)	The Company does not expect to pay a dividend in the foreseeable future.

Equity (Details - Warrant Activity)


	Warrants			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		1,597		$	8,875.44
Granted		1,544			3,220.82
Exercised		(1,407	)		2,090.82
Forfeited		–			–
Expired		(2	)		77,274.54
Outstanding, December 31, 2023		1,732			9,709.31
Granted		341,858			36.50
Exercised		(284,006	)		0.13
Forfeited		–			–
Expired		(5	)		202,500
Outstanding, December 31, 2024		59,579		$	465.88

Schedule of RSUs activity

Schedule of RSUs activity
	RSUs		Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		–	$	–
Granted		6		25,050.00
Vested		–		–
Forfeited		–		–
Non-vested, December 31, 2023		6		25,050.00
Granted		108		648.25
Vested		–		–
Forfeited		–		–
Non-vested, December 31, 2024		114	$	1,932.55

Schedule of PUs activity

Schedule of PUs activity
	PUs			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		19		$	14,581.58
Granted		–			–
Vested		–			–
Forfeited		–			–
Non-vested, December 31, 2023		19			14,581.58
Granted		–			–
Vested		(6	)		25,050.00
Forfeited		(8	)		9,750.00
Non-vested, December 31, 2024		5		$	9,750.00

Warrant [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of black-scholes option assumptions


	Year Ended December 31, 2023
Fair value of common stock on measurement date		$4,000 per share
Risk free interest rate (1)		4.72%
Volatility (2)		124.66%
Dividend yield (3)		0%
Expected term (in years)		4.2 – 5.0

(1)	The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
(2)	The trading volatility was determined by calculating the volatility of the Company.
(3)	The Company does not expect to pay a dividend in the foreseeable future.

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Equity (Details - Warrant Activity) - Warrants [Member] - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, shares	1,732	1,597
Warrants outstanding, weighted average exercise price per share	$ 9,709.31	$ 8,875.44
Warrants granted, shares	341,858	1,544
Warrants granted, weighted average exercise price per share	$ 36.50	$ 3,220.82
Warrants exercised, shares	(284,006)	(1,407)
Warrants exercised, weighted average exercise price per share	$ 0.13	$ 2,090.82
Warrants forfeited, shares	0	0
Warrants forfeited, weighted average exercise price per share	$ 0	$ 0
Warrants expired, shares	(5)	(2)
Warrants expired, weighted average exercise price per share	$ 202,500	$ 77,274.54
Warrants outstanding, shares	59,579	1,732
Warrants outstanding, weighted average exercise price per share	$ 465.88	$ 9,709.31

Equity (Details - Restricted stock units activity) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested at beginning	6	0
Weighted-average grant date fair value non-vested at beginning	$ 25,050.00	$ 0
RSUs granted	108	6
Weighted average grant date fair value granted	$ 648.25	$ 25,050.00
RSUs vested	0	0
Weighted-average grant date fair value vested	$ 0	$ 0
RSUs forfeited	0	0
Weighted-average grant date fair value forfeited	$ 0	$ 0
Non-vested at ending	114	6
Weighted-average grant date fair value non-vested at ending	$ 1,932.55	$ 25,050.00

Commitments and Contingencies

12 Months Ended

Dec. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 5 – Commitments and Contingencies

Executive Employment Agreements

On September 1, 2017, the Company entered into an employment agreement with Mr. John Climaco pursuant to which Mr. Climaco agreed to serve as Chief Executive Officer and Director of the Company commencing on such date for an initial term of three years. On September 1, 2020, the Company entered into an amendment to the employment agreement with Mr. Climaco. The amendment extends the term of employment under the Employment Agreement, which was originally for a three-year period, for additional twelve-month periods, unless and until either the Company or Mr. Climaco provides written notice to the other party not less than sixty days before such anniversary date that such party is electing not to extend the term. If the Company provides notice of its election not to extend the term, Mr. Climaco may terminate his employment at any time prior to the expiration of the term by giving written notice to the Company at least thirty days prior to the effective date of termination, and upon the earlier of such effective date of termination or the expiration of the term, Mr. Climaco shall be entitled to receive the same severance benefits as are provided upon a termination of employment by the Company without cause. Pursuant to the Amendment, the severance benefits shall be twelve months of Mr. Climaco’s base salary. Such severance payment shall be made in a single lump sum sixty days following the termination, provided that Mr. Climaco has executed and delivered to the Company and has not revoked a general release of the Company. Pursuant to the employment agreement, the compensation committee of the board of directors reviews the base salary payable to Mr. Climaco annually during the term of the agreement. On March 6, 2025, the compensation committee of the board of directors set Mr. Climaco’s annual base salary to $580,000.

On June 28, 2019, we entered into employment letters with Drs. Silberman and Picker pursuant to which Dr. Silberman agreed to commit 50% of her time to our matters; and Dr. Picker agreed to commit 25% of his time to our matters. On March 6, 2025, the compensation committee of the board of directors set Drs. Silberman and Picker annual base salaries to $247,000 and $120,000, respectively.

In March 2024, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $240,608 to the officers of the Company payable upon completion of a subsequent round of financing and a determination by the Board that such financing is sufficient for the Company's needs after payment of such bonus.

On March 6, 2025, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $631,243 to the officers of the Company.

Scientific Advisory Board

The Scientific Advisory board is consisted of one member, Dr. Sigmond Hsu. Dr. Hsu receives annual cash compensation of $68,600. As of December 31, 2024 and 2023, the Company has accrued $177,309 and $168,734, respectively, for Mr. Hsu’s Scientific Advisory Board compensation.

WP744 Portfolio (Berubicin)

On November 21, 2017, the Company entered into a Collaboration and Asset Purchase Agreement with Reata Pharmaceuticals, Inc. (“Reata”). Through this agreement, the Company purchased all of Reata’s rights, title, interest and previously conducted research and development results in the chemical compound commonly known as Berubicin. In exchange for these rights, the Company agreed to pay Reata an amount equal to 2.25% of the net sales of Berubicin for a period of 10 years from the Company’s first commercial sale of Berubicin plus $10,000. Reata also agreed to collaborate with the Company on the development of Berubicin, from time to time.

On December 28, 2017, the Company entered into a Technology Rights and Development Agreement with Houston Pharmaceuticals, Inc. (“HPI”). HPI is affiliated with Dr. Waldemar Priebe, our founder. Pursuant to this agreement, the Company obtained a worldwide exclusive license to the chemical compound commonly known as WP744. In exchange for these rights, the Company agreed to pay consideration to HPI as follows: (i) a royalty of 2% of net sales of any product utilizing WP744 for a period of ten years after the first commercial sale of such; and (ii) $100,000 upon beginning Phase II clinical trials (paid in 2021); and (iii) $200,000 upon the approval by the FDA of a New Drug Application for any product utilizing WP744; and (iv) a series of quarterly development payments totaling $750,000 beginning immediately after the Company’s raise of $7,000,000 of investment capital. In addition, the Company issued 3 shares of the Company’s common stock valued at $3,375 per share to HPI upon execution of the agreement. On November 13, 2019, the Company closed its IPO, thereby fulfilling all conditions precedent and completing the acquisition of the intellectual property discussed in the HPI agreement. During the years ended December 31, 2024 and 2023, the Company recognized $50,000 and $50,000, respectively, related to this agreement. Unrelated to this agreement, from time to time, the Company purchases pharmaceutical products from HPI which are necessary for the manufacturing of Berubicin API and drug product. During the years ended December 31, 2024 and 2023, the Company expensed $0 related to the purchase of pharmaceutical products from HPI. This agreement was terminated March 23, 2025.

On August 30, 2018, we entered into a sublicense agreement with WPD Pharmaceuticals, Inc. (“WPD”). Pursuant to the agreement, the Company granted WPD an exclusive sublicense, even as to us, for the patent rights we licensed pursuant to the HPI License within the following countries: Poland, Estonia, Latvia, Lithuania, Belarus, Ukraine, Moldova, Romania, Bulgaria, Serbia, Macedonia, Albania, Armenia, Azerbaijan, Georgia, Montenegro, Bosnia, Croatia, Slovenia, Slovakia, Czech Republic, Hungary, Chechnya, Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Greece, Austria, and Russia. The sublicense agreement provides that WPD must use commercially reasonable development efforts to attempt to develop and commercialize licensed products in the above mentioned territories, which means the expenditure of at least $2.0 million on the development, testing, regulatory approval or commercialization of the licensed products during the three year period immediately following the date of the sublicense agreement. In the event that WPD fails to use commercially reasonable development efforts by the foregoing three-year deadline, we have the right to terminate this sublicense agreement. As of December 31, 2021, the Company has received reports of the WPD expenditures related to this agreement, has conducted due inquiry into validating those expenditures, and has determined that WPD has exercised commercially reasonable development efforts and has therefore fulfilled the terms of the agreement necessary to secure their rights under the sublicense in perpetuity subject to the ongoing obligations of the sublicense. In consideration for the rights granted under the sublicense agreement, to the extent we are required to make any payments to HPI pursuant to the HPI License as a result of this sublicense agreement, WPD agreed to advance us such payments, and to pay us a royalty equal to 1% of such payments. WPD is a Polish corporation and was affiliated with Dr. Priebe. This agreement was terminated March 23, 2025.

On November 21, 2022, CNS entered into an Investigational Medicinal Product Supply Agreement with Pomeranian Medical University (“PUM”) in Szczecin, Poland. CNS agreed to sell berubicin hydrochloride drug product (and related reference standards) to PUM at a discount to the historical cost of manufacturing so that PUM may conduct an investigator-initiated clinical trial of Berubicin in CNS lymphomas. PUM agreed to pay CNS the following payments: (i) PLN 5,870 upon delivery of 2 vials each of berubicin and berubicinol reference standards, (ii) PLN 873,201 upon delivery of a first batch of 150 berubicin drug product vials, and (iii) PLN 873,201 upon delivery of a second batch of 150 berubicin drug product vials. As of December 31, 2022, the reference standards were delivered, and the Company recognized $1,302 in accounts receivable and as a reduction to research and development expense. In April 2023, the first batch of berubicin drug product vials were delivered, and the Company recognized $196,303 in accounts receivable and as a reduction to research and development expense. As of December 31, 2023, the outstanding accounts receivable balance of $197,605 was collected in full.

On August 31, 2018, the Company entered into a sublicense agreement with Animal Life Sciences, LLC (“ALI”), pursuant to which we granted ALI an exclusive sublicense, even as to us, for the patent rights we licensed pursuant to the HPI License solely for the treatment of cancer in non-human animals through any type of administration. In consideration for the rights granted under the sublicense agreement, ALI agreed to issue us membership interests in ALI equal to 1.52% of the outstanding ALI membership interests. As additional consideration for the rights granted, to the extent we are required to make any payments to HPI pursuant to the HPI License as a result of this sublicense agreement, ALI agreed to advance us such payments, and to pay us a royalty equal to 1% of such payments. Dr. Waldemar Priebe was an affiliate of ALI. This agreement was terminated March 23, 2025.

On June 10, 2020, the FDA granted Orphan Drug Designation (“ODD”) for Berubicin for the treatment of malignant gliomas. ODD from the FDA is available for drugs targeting diseases with less than 200,000 cases per year. ODD may enable market exclusivity of 7 years from the date of approval of an NDA in the United States. During that period the FDA generally could not approve another product containing the same drug for the same designated indication. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. The ODD now constitutes our primary intellectual property protections although the Company is exploring if there are other patents that could be filed related to Berubicin to extend additional protections.

On July 24, 2021, the Company received Fast Track Designation from the FDA for Berubicin. Fast Track Designation is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

WP1244 Portfolio

On January 10, 2020, Company entered into a Patent and Technology License Agreement (the “WP1244 Agreement”) with The Board of Regents of The University of Texas System, an agency of the State of Texas, on behalf of The University of Texas M. D. Anderson Cancer Center (“UTMDACC”). Pursuant to the WP1244 Agreement, the Company obtained a royalty-bearing, worldwide, exclusive license to certain intellectual property rights, including patent rights, related to the Company’s recently announced WP1244 drug technology. In consideration, the Company must make payments to UTMDACC including an up-front license fee, annual maintenance fee, milestone payments and royalty payments (including minimum annual royalties) on sales of licensed products developed under the WP1244 Agreement. The term of the WP1244 Agreement expires on the last to occur of: (a) the expiration of all patents subject to the WP1244 Agreement, or (b) fifteen years after execution; provided that UTMDACC has the right to terminate this WP1244 Agreement in the event that the Company fails to meet certain commercial diligence milestones. The commercial diligence milestones are as follows (i) initiated PC toxicology to support filing of Investigational New Drug Application (“IND”) or New Drug Application (“NDA”) for the Licensed Product within the eighteen (18) month period following the Effective Date (ii) file and IND for the Licensed Product within three (3) year period following the Effective Date and (iii) Commencement of Phase I Study within the five (5) year period following the Effective Date. The Company has not met the commercial diligence milestones and has not paid the annual maintenance fee required as of the date hereof. On May 25, 2024 the WP1244 Agreement was terminated. There are no termination penalty provisions in the Agreement. During the year ended December 31, 2024 and 2023, the Company paid $52,537 and $55,092, respectively.

Cortice Biosciences, Inc. Exclusive License Agreement

On July 29, 2024, the Company entered into an Exclusive License Agreement with Cortice Biosciences, Inc. (“Cortice”) pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights related to certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. The term of the license will expire, other than due to a breach of the Cortice Agreements, at the end of the royalty term with respect to any licensed product in any of the included territories, which begins upon the first commercial sale in such territory and ends on the latest of (i) ten years after such sale, (ii) the expiration of regulatory or marketing exclusivity for such licensed product in such country, or (c) the expiration of the last to expire valid patent claim in such country covering such licensed product. Pursuant to the Cortice Agreements, the Company agreed to issue Cortice 11,468 shares of the Company’s common stock upon the closing of the transaction, which occurred on July 29, 2024, and 867 shares of Company common stock upon the receipt of shareholder approval of such issuance as required by the rules of the Nasdaq Stock Market. The Company also agreed to make milestone payments to Cortice in either cash or shares of Company common stock (at Cortice’s option) upon: (i) meeting the primary endpoint a pivotal trial for a licensed product – either $15.0 million or 8,223 shares of Company common stock; (ii) FDA acceptance of an New Drug Application for a licensed product – either $30.0 million or 16,446 shares of Company common stock; (iii) the first commercial sale in the United States of a licensed product – either $45.0 million or 24,668 shares of Company common stock; and (iv) the first commercial sale in Japan of a licensed product – either $10.0 million or 4,112 shares of Company common stock. The Company’s obligation to pay the above milestones in Company common stock is subject to the receipt of shareholder approval as required by the rules of the Nasdaq Stock Market. The Company also agreed to pay Cortice royalties on sales of licensed products of between 3.0%-7.5%. Finally, to the extent Cortice is required to pay any milestone payments to the original holder of the intellectual property rights licensed, the Company has agreed to make such payments to Cortice. As of December 31, 2024, there were no accruals related to the milestone payments and the Company issued 11,468 Shares with a fair value of $596,303 pursuant to the Cortice Agreement.

Equity (Details - Option activity) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options outstanding, beginning balance	157	51
Weighted average exercise price per share outstanding, beginning balance	$ 56,287.36	$ 168,547.02
Options, granted	113	106
Weighted average exercise price per share, granted	$ 645.88	$ 4,460.14
Options, exercised	0	0
Weighted average exercise price per share, exercised	$ 0	$ 0
Options, forfeited	0	0
Weighted average exercise price per share, forfeited	$ 0	$ 0
Options, expired	0	0
Weighted average exercise price per share, expired	$ 0	$ 0
Options outstanding, ending balance	270	157
Weighted average exercise price per share outstanding, ending balance	$ 33,000.37	$ 56,287.36
Options, exercisable	175
Weighted average exercise price per share, exercisable	$ 48,148.42

Statements of Cash Flows - USD ($)	12 Months Ended
Statements of Cash Flows - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Cash Flows from Operating Activities:
Net loss	$ (14,857,801)	$ (18,851,226)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	838,957	1,007,417
Depreciation	3,306	4,134
Common stock issued for license agreement	596,303	0
Loss on disposal of fixed assets	(190)	498
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(59,972)	2,377,275
Accounts payable and accrued expenses	(3,633,902)	1,321,871
Net cash used in operating activities	(17,113,299)	(14,140,031)
Cash Flows from Investing Activities:
Purchase of property and equipment	(4,188)	(3,901)
Net cash used in investing activities	(4,188)	(3,901)
Cash Flows from Financing Activities:
Payments of deferred offering costs	(66,750)	(202,859)
Payments on notes payable	(300,806)	(438,733)
Proceeds from exercise of warrants	21,325	2,961,239
Proceeds from sale of common stock	23,376,375	2,317,599
Net cash provided by financing activities	23,030,144	4,637,246
Net change in cash and cash equivalents	5,912,657	(9,506,686)
Cash and cash equivalents, at beginning of period	548,721	10,055,407
Cash and cash equivalents, at end of period	6,461,378	548,721
Supplemental disclosures of cash flow information:
Cash paid for interest	13,599	13,805
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash investing and financing activities:
Prepaid expense financed with note payable	326,072	329,571
Reclassification of deferred offering costs to equity	248,972	0
Common stock issued for subscription receivable	882,539	0
Stock issued for stock split rounding	$ 2	$ 0

Equity (Details - Warrant assumptions) - Warrant [Member]

12 Months Ended

Dec. 31, 2024

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Fair value of common stock on measurement date

$4,000 per share

Risk free interest rate

4.72%

^[1]

Volatility

124.66%

^[2]

Dividend yield

0.00%

^[3]

Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expected term (in years)

4 years 2 months 12 days

Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Expected term (in years)

5 years

[1]	The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
[2]	The trading volatility was determined by calculating the volatility of the Company.
[3]	The Company does not expect to pay a dividend in the foreseeable future.

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Equity (Details - Assumptions options) - Share-Based Payment Arrangement, Option [Member]

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Fair value of common stock on measurement date

$632.50 to $646.50 per share

$1.00 to $2.40 per share

Dividend yield

^[1]

0.00%

Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Risk free interest rate

^[2]

3.80%

3.38%

Volatility

^[3]

102.25%

114.13%

Expected term (in years)

5 years 6 months

Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Risk free interest rate

^[2]

4.39%

4.37%

Volatility

^[3]

118.36%

118.09%

Expected term (in years)

6 years 3 months 18 days

[1]	The Company does not expect to pay a dividend in the foreseeable future.
[2]	The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
[3]	The trading volatility was determined by calculating the volatility of the Company’s peer group.

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Equity

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Equity

Note 4 – Equity

The Company has authorized 75,000,000 shares of common stock having a par value of $0.001 per share. In addition, the Company authorized 5,000,000 shares of preferred stock to be issued having a par value of $0.001. The specific rights of the preferred stock shall be determined by the board of directors. On May 2, 2024, the Company filed a Certificate of Amendment to its Amended and Restated Articles of Incorporation with the Secretary of State of the State of Nevada to increase the number of the Company’s authorized shares of common stock from 75,000,000 shares to 300,000,000 shares.

On April 30, 2024, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion prior to the one-year anniversary of the annual meeting.

Pursuant to such authority granted by the Company’s stockholders, the Company’s board of directors approved a one-for-fifty (1:50) reverse stock split of the Company’s common stock and the filing of the Amendment to effectuate the reverse split. The reverse stock split became effective on June 4, 2024 on a 1-for-50 basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.

On April 30, 2024, the Company held its scheduled 2024 Annual Meeting of Stockholders at which the Company’s stockholders approved amendments to the Company's 2020 Equity Plan (the “2020 Plan”) including an increase in the number of shares of common stock, par value $0.001 per share, authorized for issuance under the 2020 Plan by 1,400 shares. As amended, the number of shares of the common stock that may be issued under the 2020 Plan is 1,739 shares (this includes the 1,400 share increase).

On November 26, 2024, the stockholders of the Company approved an amendment to the Company’s amended and restated articles of incorporation (the “Amendment”) to effect the reverse stock split at a ratio in the range of 1-for-2 to 1-for-50, with such ratio to be determined in the discretion of the Company’s board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s board of directors in its sole discretion prior to the one-year anniversary of the annual meeting.

Pursuant to such authority granted by the Company’s stockholders, the Company’s board of directors approved a one-for-fifty (1:50) reverse stock split of the Company’s common stock and the filing of the Amendment to effectuate the reverse split. The reverse stock split became effective on February 21, 2025 on a 1-for-50 basis without any change in the par value per share, which remained at $0.001. The reverse stock split has been retroactively adjusted throughout these financial statements and footnotes.

Common Stock

2024

On January 29, 2024, the Company entered into a placement agency agreement with A.G.P./Alliance Global Partners (“AGP”) and Maxim Group LLC (“Maxim” and collectively with AGP, the “Placement Agents”) (the “Placement Agreement”) for the public offering by the Company of (i) 889 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) (ii) pre-funded warrants to purchase 4,448 shares of Common Stock (the “Pre-Funded Warrants”); (iii) Series A Warrants to purchase up to an aggregate of 5,342 shares of Common Stock (the “Series A Warrants”); and (iv) Series B Warrants to purchase up to an aggregate of 5,342 shares of Common Stock (the “Series B Warrants”, and together with the Series A Warrants, the “Common Warrants)). The Common Warrants and Pre-Funded Warrants are collectively referred to herein as the (“Warrants”). The combined purchase price of one share of Common Stock and accompanying Common Warrants was $750.00 and the combined purchase price of one Pre-Funded Warrant and accompanying Common Warrants was $747.50. In connection with the offering, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors that participated in the offering. As of December 31, 2024, 4,448 of the Pre-Funded Warrants have been exercised. The closing of the sales of these securities occurred on February 1, 2024. The net proceeds to the Company from the offering were $3,331,000, after deducting the placement agents’ fees and other offering expenses.

On June 14, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 6,720 shares of the Company’s common stock and pre-funded warrants to purchase 601 shares of common stock in lieu thereof (the “June 14 Pre-Funded Warrants”) in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 7,321 shares of common stock (the “June 14 Common Warrants”). The combined purchase price of one share of common stock (or pre-funded warrant in lieu thereof) and accompanying June 14 Common Warrant was $187.50. The closing of this offering and private placement occurred on June 17, 2024.

Subject to certain ownership limitations, each of the June 14 Common Warrants is immediately exercisable, has an exercise price of $181.00 per share, and expire five years from the date of issuance. Each June 14 Pre-Funded Warrant is exercisable into one share of common stock at a price per share of $0.05 (as adjusted from time to time in accordance with the terms thereof). The gross proceeds to the Company from the offering was approximately $1.37 million, resulting in net proceeds, after payment of commissions and expenses, received by the Company of $1,203,267.

On June 26, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 11,360 shares of the Company’s common stock in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 11,360 shares of common stock (the “June 26 Common Warrants”). The combined purchase price of one share of common stock and accompanying June 26 Common Warrant was $122.50. The closing of the offering and private placement occurred on June 27, 2024 (the “Closing Date”).

Subject to certain ownership limitations, each of the June 26 Common Warrants is immediately exercisable, has an exercise price of $116.00 per share, and expire five years from the date of issuance. The June 26 Common Warrants may only be exercised on a cashless basis if there is no registration statement registering, or a prospectus contained therein in not available for, the resale of the shares of common stock underlying the June 26 Common Warrants. The gross proceeds to the Company from the offering were approximately $1.39 million resulting in net proceeds, after payment of commissions and expenses, received by the Company of $1,221,146.

On July 3, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 28,500 shares of the Company’s common stock in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 28,500 shares of common stock (the “July 3 Common Warrants”). The combined purchase price of one share of common stock and accompanying July 3 Common Warrant is $69.50. The closing of this offering and private placement occurred on July 5, 2024.

Subject to certain ownership limitations, each of the July 3 Common Warrants is immediately exercisable, has an exercise price of $63.00 per share, and expire five years from the date of issuance. The gross proceeds to the Company from the offering were approximately $1.98 million, before deducting the financial advisor fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Common Warrants. After payment of commissions and expenses, the proceeds received by the Company was $1,787,000.

On July 26, 2024, the Company entered into a Sales Agreement (the “AGP ATM Sales Agreement”) with A.G.P./Alliance Global Partners (“AGP”). Pursuant to the terms of the AGP ATM Sales Agreement, the Company originally was permitted to sell from time to time through AGP, as sales agent or principal, shares of the Company’s common stock, par value $0.001 per share with initial aggregate sales price of up to $5.2 million. On July 30, 2024, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to $25.0 million (not including the original $5.2 million). On March 20, 2025, the Company increased the aggregate sales price of common shares that may be sold under the AGP ATM Sales Agreement to $43.5 million (including $6.4 million remaining from the previous increase). As of December 31, 2024, the Company has sold 991,773 Shares pursuant to the AGP ATM Sales Agreement for net proceeds of approximately $13.7 million. $882,539 of the net proceeds was deposited on January 10, 2025. As of December 31, 2024, the Company recorded a subscription receivable for $882,539.

On October 23, 2024, the Company entered into securities purchase agreements with institutional investors for the sale by the Company of 74,000 shares of the Company’s common stock in a registered direct offering. In a concurrent private placement, the Company also sold to the investors unregistered warrants to purchase up to an aggregate of 278,943 shares of common stock (the “July 3 Common Warrants”). The per share purchase price of each share of common stock was $8.50 per share and the purchase price for each Pre-Funded Warrant was $8.45 per Pre-Funded Warrant. The closing of this offering and private placement occurred on October 23, 2024.

Subject to certain ownership limitations, each of the October 23 Common Warrants is immediately exercisable, has an exercise price of $0.05 per share, and expire five years from the date of issuance. The gross proceeds to the Company from the offering were approximately $3 million, before deducting the financial advisor fees and other estimated offering expenses payable by the Company, and excluding the proceeds, if any, from the exercise of the Common Warrants. After payment of commissions and expenses, the proceeds received by the Company was $2,725,907.

Common share issued for license agreement

On July 29, 2024, the Company entered into an Exclusive License Agreement and Stock Purchase Agreement (collectively, the “Cortice Agreements”) with Cortice Biosciences, Inc. (“Cortice”) pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights related to certain patents around the compound TPI 287 in the United States, Canada, Mexico and Japan. The term of the license will expire, other than due to a breach of the Cortice Agreements, at the end of the royalty term with respect to any licensed product in any of the included territories, which begins upon the first commercial sale in such territory and ends on the latest of (i) ten years after such sale, (ii) the expiration of regulatory or marketing exclusivity for such licensed product in such country, or (c) the expiration of the last to expire valid patent claim in such country covering such licensed product.

Pursuant to the Cortice Agreements, the Company agreed to issue Cortice 11,468 shares of the Company’s common stock upon the closing of the transaction, which occurred on July 29, 2024, and 867 shares of Company common stock upon the receipt of shareholder approval of such issuance as required by the rules of the Nasdaq Stock Market. The Company also agreed to make milestone payments to Cortice in either cash or shares of Company common stock (at Cortice’s option) upon: (i) meeting the primary endpoint a pivotal trial for a licensed product – either $15.0 million or 8,223 shares of Company common stock; (ii) FDA acceptance of an New Drug Application for a licensed product – either $30.0 million or 16,446 shares of Company common stock; (iii) the first commercial sale in the United States of a licensed product – either $45.0 million or 24,668 shares of Company common stock; and (iv) the first commercial sale in Japan of a licensed product – either $10.0 million or 4,112 shares of Company common stock. The Company’s obligation to pay the above milestones in Company common stock is subject to the receipt of shareholder approval as required by the rules of the Nasdaq Stock Market. The Company also agreed to pay Cortice royalties on sales of licensed products of between 3.0%-7.5%. Finally, to the extent Cortice is required to pay any milestone payments to the original holder of the intellectual property rights licensed, the Company has agreed to make such payments to Cortice. As of December 31, 2024, there were no accruals related to the milestone payments and the Company issued 11,468 Shares with a fair value of $596,303 pursuant to the Cortice Agreement.

2023

Pursuant to the terms of the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC (collectively, the “Agent”), the Company may sell from time to time, through the Agent, shares of the Company’s common stock with an aggregate sales price of up to $20.0 million. During the year ended December 31, 2023, the Company sold 342 shares of common stock to the Agent for net proceeds of $2,317,599.

During the year ended December 31, 2023, the Company issued 1,497 shares of common stock from the exercise of warrants.

Stock Options

In 2017, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2017 Stock Plan (the “2017 Plan”). The 2017 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 27 shares of common stock.

In 2020, the Board of Directors of the Company approved the CNS Pharmaceuticals, Inc. 2020 Stock Plan (the “2020 Plan”). The 2020 Plan allows for the Board of Directors to grant various forms of incentive awards for up to 40 shares of common stock. The 2020 Plan was amended effective as of August 9, 2023, which was approved by the Company’s stockholders at the Company’s annual meeting on September 14, 2023. The amendment increased the 2020 Plan by 298 shares of common stock.

2024

On January 19, 2024, the Board of Directors of the Company approved the issuance of 5 options to Ms. Mahery as compensation for her appointment to our Board of Directors. The options have a ten-year term at an exercise price of $632.50 and vest in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $2,728.

On April 7, 2024, the Board of Directors approved grants of 108 options to officers, employees, and board of directors. The options have a ten-year term at an exercise price of $646.5. Of the 108 options issued, 35 options vest on the first anniversary or at the time of the 2025 shareholder meeting, whichever occurs first and 73 options vest in 36 equal monthly installments over 3 years. The total fair value of these option grants at issuance was $58,335.

2023

On March 29, 2023, the Board of Directors approved, based upon the recommendation of the Compensation Committee, cash bonuses totaling $550,750 to the officers of the Company. In addition, the officers and an employee were awarded a total of 12 options with a ten-year term at an exercise price of $2,490. Of the options issued, 50% vest over 2 years and 50% vest upon the Company’s common stock price exceeding various closing prices ranging from $6.00 - $24.00 per share. The total fair value of these option grants at issuance was $25,820.

On May 3, 2023, the Board of Directors of the Company appointed Bettina M. Cockroft, M.D., M.B.A as an independent member of the Company’s Board of Directors. Dr. Cockroft was granted a ten-year option to purchase 1 share of Company common stock at an exercise price of $4,175 vesting in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $3,514.

On August 4, 2023, the Board of Directors approved the issuance of 3 options to Dr. Cockroft. The options have a ten-year term at an exercise price of $5,675 and vest in 36 equal monthly installments succeeding the issuance date. The total fair value of these option grants at issuance was $12,771.

On August 27, 2023, the Board of Directors approved the issuance of 79 options to the board of directors. The options have a ten-year term at an exercise price of $4,750 and vest on the first anniversary date of issuance. The total fair value of these option grants at issuance was $313,846.

During the years ended December 31, 2024 and 2023, the Company recognized $684,181 and $949,982 of stock-based compensation, respectively, related to outstanding stock options. At December 31, 2024, the Company had $94,968 of unrecognized expenses related to options.

The following table summarizes the stock option activity for the years ended December 31, 2024 and 2023:

Schedule of stock option activity
	Options		Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		51	$	168,547.02
Granted		106		4,460.14
Exercised		–		–
Forfeited		–		–
Expired		–		–
Outstanding, December 31, 2023		157		56,287.36
Granted		113		645.88
Exercised		–		–
Forfeited		–		–
Expired		–		–
Outstanding, December 31, 2024		270	$	33,000.37
Exercisable, December 31, 2024		175	$	48,148.42

The aggregate fair value of the options measured during the years ended December 31, 2024 and 2023 were calculated using the Black-Scholes option pricing model based on the following assumptions:


	Year Ended	Year Ended
	December 31, 2024	December 31, 2023
Fair value of common stock on measurement date	$632.50 to $646.50 per share	$1.00 to $2.40 per share
Risk free interest rate (1)	3.80% to 4.39%	3.38% to 4.37%
Volatility (2)	102.25% to 118.36%	114.13% to 118.09%
Dividend yield (3)	0%	0%
Expected term (in years)	5.5 – 6.3	5.5 – 6.3

(1)	The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
(2)	The trading volatility was determined by calculating the volatility of the Company’s peer group.
(3)	The Company does not expect to pay a dividend in the foreseeable future.

As of December 31, 2024, the outstanding stock options have a weighted average remaining term of 8.16 years and the aggregate intrinsic value of options vested and outstanding was $0. As of December 31, 2024, there were no awards remaining to be issued under the 2017 Plan and 28 awards remaining to be issued under the 2020 Plan.

As of December 31, 2023, the outstanding stock options have a weighted average remaining term of 8.54 years and the aggregate intrinsic value of options vested and outstanding was $8,217.

Stock Warrants

The following table summarizes the stock warrant activity for the years ended December 31, 2024 and 2023:


	Warrants			Weighted-Average Exercise Price Per Share
Outstanding, December 31, 2022		1,597		$	8,875.44
Granted		1,544			3,220.82
Exercised		(1,407	)		2,090.82
Forfeited		–			–
Expired		(2	)		77,274.54
Outstanding, December 31, 2023		1,732			9,709.31
Granted		341,858			36.50
Exercised		(284,006	)		0.13
Forfeited		–			–
Expired		(5	)		202,500
Outstanding, December 31, 2024		59,579		$	465.88

On October 16, 2023, the Company entered into a warrant exercise inducement offer letter (the “Inducement Letter”) with a holder of certain existing warrants (“Holder”) to receive new warrants to purchase up to a number of shares of common stock equal to 200% (the “Inducement Warrants”) of the number of warrant shares issued pursuant to the exercise of such certain existing warrants to purchase shares of common stock (the “Existing Warrants”) pursuant to which the Holder agreed to exercise for cash their Existing Warrants to purchase up to 751 shares of the Company’s common stock, at a Reduced Exercise Price (as defined below), in exchange for the Company’s agreement to issue the Inducement Warrants to purchase up to 1,502 shares of the Company’s common stock (the “Inducement Warrant Shares”). The Existing Warrants consist of: (i) warrants, originally issued on December 22, 2020 and amended on December 5, 2022; (ii) warrants, originally issued on January 10, 2022 and amended on December 5, 2022; and (iii) warrants issued on December 5, 2022. Pursuant to the Inducement Letter, the exercise price for such Existing Warrants was reduced to $3,200 per share (the “Reduced Exercise Price”). In connection with the warrant inducement, the Company estimated the fair value of the warrants based on the Black-Scholes option pricing model and recorded a deemed dividend to additional paid in capital of $5,571,694.

The aggregate fair value of the warrants measured during the year ended December 31, 2023 were calculated using the Black-Scholes option pricing model based on the following assumptions:


	Year Ended December 31, 2023
Fair value of common stock on measurement date		$4,000 per share
Risk free interest rate (1)		4.72%
Volatility (2)		124.66%
Dividend yield (3)		0%
Expected term (in years)		4.2 – 5.0

(1)	The risk-free interest rate was determined by management using the market yield on U.S. Treasury securities with comparable terms as of the measurement date.
(2)	The trading volatility was determined by calculating the volatility of the Company.
(3)	The Company does not expect to pay a dividend in the foreseeable future.

During the year ended December 31, 2024, the Company received $21,325 in net cash proceeds from the exercise of 4,448 warrants issued at an exercise price of $2.5, 14 warrants issued at an exercise price of $750 and 279,944 warrants issued at an exercise price of $0.05. As of December 31, 2024, the remaining weighted average term for the outstanding stock warrant is 4.09 years.

During the year ended December 31, 2023, the Company received $2,961,239 in net cash proceeds from the exercise of 753 warrants issued at an exercise price of $3,200, 96 warrants issued at an exercise price of $7,575 and 650 warrants previously issued at an exercise price of $2.5.

As of December 31, 2023 the outstanding and exercisable warrants have a weighted average remaining term of 4.64 years and an intrinsic value of $15,245.

Restricted Stock Units

On April 7, 2024, the Board of Directors approved grants of 108 RSUs to officers, employees, and board of directors. Of the 108 RSUs issued, 35 RSUs vest on the first anniversary or at the time of the 2025 shareholder meeting, whichever occurs first and 73 RSUs vest in 8 equal quarterly installments over 2 years. The Company valued the RSUs based on the stock price at grant which total $58,335.

During the years ended December 31, 2024 and 2023, the Company recognized $54,414 and $23,850 of stock-based compensation, related to outstanding RSUs, respectively. At December 31, 2024, the Company had $68,275 of unrecognized expenses related to outstanding RSUs.

The following table summarizes the RSUs activity for the years ended December 31, 2024 and 2023:

Schedule of RSUs activity
	RSUs		Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		–	$	–
Granted		6		25,050.00
Vested		–		–
Forfeited		–		–
Non-vested, December 31, 2023		6		25,050.00
Granted		108		648.25
Vested		–		–
Forfeited		–		–
Non-vested, December 31, 2024		114	$	1,932.55

Performance Units

During the years ended December 31, 2024 and 2023, the Company recognized $100,362 and $33,585 related to outstanding stock PUs, respectively. At December 31, 2024, the Company had $0 of unrecognized expenses related to PUs.

The following table summarizes the PUs activity for the years ended December 31, 2024 and 2023:

Schedule of PUs activity
	PUs			Weighted-Average Grant Date Fair Value
Non-vested, December 31, 2022		19		$	14,581.58
Granted		–			–
Vested		–			–
Forfeited		–			–
Non-vested, December 31, 2023		19			14,581.58
Granted		–			–
Vested		(6	)		25,050.00
Forfeited		(8	)		9,750.00
Non-vested, December 31, 2024		5		$	9,750.00

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2022	$ 1	$ 58,848,532	$ (50,715,677)	$ 8,132,856
Beginning balance, shares at Dec. 31, 2022	636
Common stock issued for cash, net		2,317,599		2,317,599
Common stock issued for cash, net, shares	342
Exercise of warrants, net	$ 1	2,961,238		2,961,239
Exercise of warrants, net, shares	1,507
Stock-based compensation		1,007,417		1,007,417
Stock-based compensation, shares	1
Net loss			(18,851,226)	(18,851,226)
Ending balance, value at Dec. 31, 2023	$ 2	65,134,786	(69,566,903)	(4,432,115)
Ending balance, shares at Dec. 31, 2023	2,486
Common stock issued for cash and warrants, net	$ 1,114	24,008,828		24,009,942
Common stock issued for cash and warrants, net, shares	1,113,242
Exercise of warrants, net	$ 284	21,041		21,325
Exercise of warrants, net, shares	284,006
Stock-based compensation		838,957		838,957
Shares issued for license agreement	$ 12	596,291		596,303
Shares issued for license agreement, shares	11,468
Stock issued for stock split rounding	$ 2	(2)	0	0
Stock issued for stock split rounding, shares	2,354
Net loss			(14,857,801)	(14,857,801)
Ending balance, value at Dec. 31, 2024	$ 1,414	$ 90,599,901	$ (84,424,704)	$ 6,176,611
Ending balance, shares at Dec. 31, 2024	1,413,556

Balance Sheets - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 6,461,378	$ 548,721
Deferred offering costs	20,637	202,859
Subscription receivable	882,539	0
Prepaid expenses and other current assets	1,293,954	839,590
Total current assets	8,658,508	1,591,170
Noncurrent Assets:
Prepaid expenses, net of current portion	36,430	104,750
Property and equipment, net	6,005	4,933
Total noncurrent assets	42,435	109,683
Total Assets	8,700,943	1,700,853
Current Liabilities:
Accounts payable and accrued expenses	2,198,260	5,832,162
Notes payable	326,072	300,806
Total current liabilities	2,524,332	6,132,968
Total Liabilities	2,524,332	6,132,968
Commitments and contingencies
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value, 5,000,000 shares authorized and 0 shares issued and outstanding	0	0
Common stock, $0.001 par value, 300,000,000 shares authorized and 1,413,556 and 2,486 shares issued and outstanding, respectively	1,414	2
Additional paid-in capital	90,599,901	65,134,786
Accumulated deficit	(84,424,704)	(69,566,903)
Total Stockholders' Equity (Deficit)	6,176,611	(4,432,115)
Total Liabilities and Stockholders' Equity (Deficit)	$ 8,700,943	$ 1,700,853

Statements of Operations - USD ($)	12 Months Ended
Statements of Operations - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Operating expenses:
General and administrative	$ 5,611,800	$ 4,769,502
Research and development	9,290,143	14,095,606
Total operating expenses	14,901,943	18,865,108
Loss from operations	(14,901,943)	(18,865,108)
Other income (expenses):
Interest income	60,262	27,687
Interest expense	(16,120)	(13,805)
Total other income (expense)	44,142	13,882
Net loss	$ (14,857,801)	$ (18,851,226)
Loss per share - basic	$ (38.87)	$ (12,509.11)
Loss per share - diluted	$ (38.87)	$ (12,509.11)
Weighted average shares outstanding - basic	382,241	1,507
Weighted average shares outstanding - diluted	382,241	1,507

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Note 2 – Summary of Significant Accounting Policies

The accompanying financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and in accordance with the rules and regulations of the United States Securities and Exchange Commission (the “SEC”). The Company’s fiscal year end is December 31.

Use of Estimates in Financial Statement Presentation - The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Liquidity and Going Concern - These financial statements have been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The continuation of the Company as a going concern is dependent upon the ability of the Company to obtain equity financings to continue operations. The Company has a history of and expects to continue to report negative cash flows from operations and a net loss. Management believes that the cash on hand, combined with aggressive working capital management, will allow us to continue operating Within one year after the date that the financial statements are issued. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company may seek additional funding through a combination of equity offerings, debt financings, government or other third-party funding, commercialization, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements and delay planned cash outlays or a combination thereof. Management cannot be certain that such events or a combination thereof can be achieved.

Cash and Cash Equivalents - The Company considers all highly liquid accounts with original maturities of three months or less at the date of acquisition to be cash equivalents. Periodically, the Company may carry cash balances at financial institutions in excess of the federally insured limit of $250,000. The amount in excess of the FDIC insurance at December 31, 2023 was $6,211,378. The Company has not experienced losses on these accounts and management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant.

Property and Equipment - Property and equipment is recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:

Schedule of estimated useful lives
Leasehold improvement	Shorter of estimated useful lives or the term of the lease
Computer equipment	3 years
Machinery and equipment	5 years
Furniture and office equipment	7 years

Repairs and maintenance costs are expensed as incurred.

Impairment of Long-lived Assets - The Company evaluates its long-lived tangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of a long-lived asset is measured by comparison of the carrying amount to the expected future undiscounted cash flows that the asset is expected to generate. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value.

Fair Value of Financial Instruments - The carrying value of short-term instruments, including cash and cash equivalents, accounts payable and accrued expenses, and short-term notes approximate fair value due to the relatively short period to maturity for these instruments.

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company utilizes a three-level valuation hierarchy for disclosures of fair value measurements, defined as follows:

Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments.

Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

Related Parties - The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of reported assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company must then assess the likelihood that the resulting deferred tax assets will be realized. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

The Company accounts for uncertain tax positions in accordance with the provisions of Accounting Standards Codification (ASC) 740-10 which prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken, or expected to be taken, on its tax return. The Company evaluates and records any uncertain tax positions based on the amount that management deems is more likely than not to be sustained upon examination and ultimate settlement with the tax authorities in the tax jurisdictions in which it operates.

Stock-based Compensation - Employee and non-employee share-based compensation is measured at the grant date, based on the fair value of the award, and is recognized as an expense over the requisite service period.

Restricted Stock Units (“RSUs”) - Our RSUs vest over two or four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant.

Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board.

Loss Per Common Share - Basic loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of December 31, 2024, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 59,579 common shares, unvested restricted stock units of 114 common shares, unvested performance units of 5 and options for 270 common shares, respectively. As of December 31, 2023, the Company’s potentially dilutive shares and options, which were not included in the calculation of net loss per share, included warrants to purchase 1,732 common shares, unvested restricted stock units of 6 common shares, unvested performance units of 19 and options for 157 common shares, respectively.

Research and Development Costs - Research and development costs are expensed as incurred. The Company recognized the benefit of refundable research and development tax credits as a reduction of research and development expenses when there is reasonable assurance that the amount claimed will be recovered.

Segments Reporting

The Company manages its operations as a single segment for the purpose of assessing performance and making operating decisions. The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The CODM allocates resources and evaluates the performance of the Company using information about combined net income from operations. All significant operating decisions are based upon an analysis of the Company as one operating segment, which is the same as its reporting segment. See statement of operations for information about combined net income from operations.

Recent Accounting Pronouncements

In November 2023, the FASB issued ASU No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosure.” The ASU updates reportable segment disclosure requirements, primarily through requiring enhanced disclosures about significant segment expenses and information used to assess segment performance. The amendments do not change how segments are determined, aggregated, or how thresholds are applied to determine reportable segments. We adopted ASU No. 2023-07 during the year ended December 31, 2024.

In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses” to improve disclosures about the nature of expenses in commonly presented financial statement captions. ASU 2024-03 is effective for all public business entities for annual reporting periods beginning after December 15, 2026, on either a prospective or retrospective basis. Early adoption permitted. Management is currently evaluating the impact of this accounting standard update on its consolidated financial statements and related disclosures.

Commitments and Contingencies (Details Narrative) - USD ($)			12 Months Ended
	Mar. 06, 2025	Jul. 29, 2024	Dec. 31, 2024	Dec. 31, 2023	Mar. 31, 2024	Apr. 30, 2023	Dec. 31, 2022
Product Liability Contingency [Line Items]
Stock issued, value			$ 1,414	$ 2
Cortice Agreements [Member] \| Common Stock [Member]
Product Liability Contingency [Line Items]
Stock Issued During Period, Shares, New Issues		11,468
Stock issued, value			596,303
Houston Pharmaceuticals [Member]
Product Liability Contingency [Line Items]
Cost of goods and services sold			0	0
Closing Of The Transaction [Member] \| Cortice Agreements [Member] \| Common Stock [Member]
Product Liability Contingency [Line Items]
Stock Issued During Period, Shares, New Issues		11,468
Nasdaq Required Shareholder Approval [Member] \| Cortice Agreements [Member] \| Common Stock [Member]
Product Liability Contingency [Line Items]
Stock Issued During Period, Shares, New Issues		867
Officers [Member]
Product Liability Contingency [Line Items]
Cash bonuses approved					$ 240,608
Mr Hsu Scientific Advisory Board [Member]
Product Liability Contingency [Line Items]
Accrued expenses related to compensation			177,309	168,734
Houston Pharm [Member] \| Technology Rights And Development Agreement [Member]
Product Liability Contingency [Line Items]
Royalty income, nonoperating			50,000	50,000
Pum [Member]
Product Liability Contingency [Line Items]
Accounts receivable				197,605		$ 196,303	$ 1,302
UTMDACC [Member] \| Patent And Technology License Agr [Member]
Product Liability Contingency [Line Items]
License fee			$ 52,537	$ 55,092
Subsequent Event [Member] \| Officers [Member]
Product Liability Contingency [Line Items]
Cash bonuses approved	$ 631,243
Mr Climaco [Member] \| Subsequent Event [Member]
Product Liability Contingency [Line Items]
Annual base salary	580,000
Drs Silberman [Member] \| Subsequent Event [Member]
Product Liability Contingency [Line Items]
Annual base salaries	247,000
Picker [Member] \| Subsequent Event [Member]
Product Liability Contingency [Line Items]
Annual base salaries	$ 120,000

Equity (Details Narrative) - USD ($)																			12 Months Ended
Equity (Details Narrative) - USD ($)	Feb. 21, 2025	Jan. 10, 2025	Nov. 26, 2024	Oct. 23, 2024	Jul. 29, 2024	Jul. 26, 2024	Jul. 03, 2024	Jun. 26, 2024	Jun. 14, 2024	Jun. 04, 2024	Apr. 07, 2024	Jan. 29, 2024	Jan. 19, 2024	Aug. 27, 2023	Aug. 09, 2023	Aug. 04, 2023	May 03, 2023	Mar. 29, 2023	Dec. 31, 2024	Dec. 31, 2023	May 01, 2024	Apr. 30, 2024	Oct. 16, 2023	Dec. 31, 2020	Dec. 31, 2017
Class of Stock [Line Items]
Common stock shares authorized																			300,000,000	300,000,000	75,000,000
Common stock par value																			$ 0.001	$ 0.001
Preferred stock shares authorized																			5,000,000	5,000,000
Preferred stock par value																			$ 0.001	$ 0.001
Reverse stock split			1-for-50							1-for-50
Subscription receivable																			$ 882,539	$ 0
Stock issued, shares																			1,413,556	2,486
Stock issued, value																			$ 1,414	$ 2
Proceeds from common stock																			23,376,375	2,317,599
Share based compensation expense																			$ 838,957	$ 1,007,417
Weighted average remaining term																			8 years 1 month 28 days	8 years 6 months 14 days
Aggregate intrinsic value																			$ 0	$ 8,217
Estimated fair value of warrants																			5,571,694
Proceeds from warrant exercises																			$ 21,325	$ 2,961,239
Warrant Exercise Price of $2.5 [Member]
Class of Stock [Line Items]
Warrants exercised, shares																			4,448	650
Warrant Exercise Price of $750 [Member]
Class of Stock [Line Items]
Warrants exercised, shares																			14
custom:Warrant Price $0.05 [Member]
Class of Stock [Line Items]
Warrants exercised, shares																			279,944
Warrant Exercise Price of $3,200 [Member]
Class of Stock [Line Items]
Warrants exercised, shares																				753
Warrant Exercise Price of $7,575 [Member]
Class of Stock [Line Items]
Warrants exercised, shares																				96
Equity Option [Member]
Class of Stock [Line Items]
Share based compensation expense																			$ 684,181	$ 949,982
Unrecognized compensation expense																			$ 94,968
Existing Warrants [Member]
Class of Stock [Line Items]
Warrants to purchase																							751
Inducement Warrant Shares [Member]
Class of Stock [Line Items]
Warrants to purchase																							1,502
Warrants [Member]
Class of Stock [Line Items]
Weighted average remaining term																				4 years 7 months 20 days
Aggregate intrinsic value of warrants outstanding																				$ 15,245
Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Exercise price																			$ 648.25	$ 25,050.00
Share based compensation expense																			$ 54,414	$ 23,850
Unrecognized compensation expense																			$ 68,275
Performance Units [Member]
Class of Stock [Line Items]
Exercise price																			$ 0	$ 0
Share based compensation expense																			$ 100,362	$ 33,585
Unrecognized compensation expense																			$ 0
Officer [Member]
Class of Stock [Line Items]
Cash bonuses awarded																		$ 550,750
Ms Mahery [Member]
Class of Stock [Line Items]
Options granted													5
Exercise Of Warrants [Member]
Class of Stock [Line Items]
Stock issued from exercise of warrants, shares																				1,497
Agent [Member]
Class of Stock [Line Items]
Issuance of common stock shares																				342
Proceeds from common stock																				$ 2,317,599
Board Of Directors [Member]
Class of Stock [Line Items]
Options granted														79
Exercise price											$ 646.5		$ 632.50	$ 4,750
Fair value of options granted											$ 58,335		$ 2,728
Options granted											108
Options issued											108
Options vested											73
Vesting description														vest on the first anniversary date of issuance
Board Of Directors [Member] \| Restricted Stock Units (RSUs) [Member]
Class of Stock [Line Items]
Fair value of options granted											$ 58,335
Options granted											108
Options issued											108
Board Of Directors [Member] \| Restricted Stock Units (RSUs) [Member] \| Share-Based Payment Arrangement, Tranche One [Member]
Class of Stock [Line Items]
Number of shares vested											35
Board Of Directors [Member] \| Restricted Stock Units (RSUs) [Member] \| Share-Based Payment Arrangement, Tranche Two [Member]
Class of Stock [Line Items]
Number of shares vested											73
Board Of Directors [Member] \| Shareholder [Member]
Class of Stock [Line Items]
Options vested											35
Officers And An Employee [Member]
Class of Stock [Line Items]
Options granted																		12
Exercise price																		$ 2,490
Fair value of options granted																		$ 25,820
Vesting description																		50% vest over 2 years and 50% vest upon the Company’s common stock price exceeding various closing prices ranging from $6.00 - $24.00 per share
Bettina Cockroft [Member]
Class of Stock [Line Items]
Options granted																3
Exercise price																$ 5,675	$ 4,175
Fair value of options granted														$ 313,846		$ 12,771	$ 3,514
Vesting description																vest in 36 equal monthly installments succeeding the issuance date	vesting in 36 equal monthly installments succeeding the issuance date
January 2024 Public Offering [Member]
Class of Stock [Line Items]
Net proceeds from the sale of equity												$ 3,331,000
June 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Net proceeds from the sale of equity								$ 1,221,146	$ 1,203,267
Gross proceeds from the sale of equity								$ 1,390,000	$ 1,370,000
July 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Net proceeds from the sale of equity							$ 1,787,000
Gross proceeds from the sale of equity							$ 1,980,000
AGPATM Sales Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock shares																			991,773
Net proceeds from the sale of equity						$ 13,700,000													$ 13,700,000
Subscription receivable																			$ 882,539
October 2024 Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Net proceeds from the sale of equity				$ 2,725,907
Gross proceeds from the sale of equity				$ 3,000,000
Subsequent Event [Member]
Class of Stock [Line Items]
Reverse stock split	1-for-50
Subsequent Event [Member] \| AGPATM Sales Agreement [Member]
Class of Stock [Line Items]
Net proceeds from the sale of equity		$ 882,539
Equity Plan 2020 [Member]
Class of Stock [Line Items]
Common stock authorized for issuance																						1,739
Plan 2017 [Member]
Class of Stock [Line Items]
Shares authorized under plan																									27
Options granted																			0
Plan 2020 [Member]
Class of Stock [Line Items]
Shares authorized under plan																								40
Additional shares authorized under plan															298
Options granted																			28
Common Stock [Member]
Class of Stock [Line Items]
Common stock shares authorized																					75,000,000
Common stock par value																			$ 0.001
Common Stock [Member] \| January 2024 Public Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares												889
Common Stock [Member] \| June 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares								11,360	6,720
Common Stock [Member] \| July 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares							28,500
Common Stock [Member] \| October 2024 Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock shares				74,000
Common Stock [Member] \| Cortice Agreements [Member]
Class of Stock [Line Items]
Issuance of common stock shares					11,468
Stock issued, shares																			11,468
Stock issued, value																			$ 596,303
Common Stock [Member] \| Cortice Agreements [Member] \| Closing Of The Transaction [Member]
Class of Stock [Line Items]
Issuance of common stock shares					11,468
Common Stock [Member] \| Cortice Agreements [Member] \| Nasdaq Required Shareholder Approval [Member]
Class of Stock [Line Items]
Issuance of common stock shares					867
Pre Funded Warrants [Member] \| January 2024 Public Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares												4,448
Warrants exercised, shares																			4,448
Pre Funded Warrants [Member] \| June 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares									601
Series A Warrants [Member] \| January 2024 Public Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares												5,342
Series B Warrants [Member] \| January 2024 Public Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares												5,342
June 2014 Common Warrants [Member] \| June 2024 Private Placement [Member]
Class of Stock [Line Items]
Issuance of common stock shares									7,321
June 26 Common Warrants [Member] \| June 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares								11,360
July 3 Common Warrants [Member] \| July 2024 Registered Direct Offering [Member]
Class of Stock [Line Items]
Issuance of common stock shares							28,500
July 3 Common Warrants [Member] \| October 2024 Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Issuance of common stock shares				278,943

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Use of Estimates in Financial Statement Presentation

Liquidity and Going Concern

Cash and Cash Equivalents

Property and Equipment

Property and Equipment - Property and equipment is recorded at cost and depreciated over their estimated useful lives using the straight-line depreciation method as follows:

Schedule of estimated useful lives
Leasehold improvement	Shorter of estimated useful lives or the term of the lease
Computer equipment	3 years
Machinery and equipment	5 years
Furniture and office equipment	7 years

Repairs and maintenance costs are expensed as incurred.

Impairment of Long-lived Assets

Fair Value of Financial Instruments

Level 1 - inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 3 - inputs to the valuation methodology are unobservable and significant to the fair value.

The Company does not have any assets or liabilities that are required to be measured and recorded at fair value on a recurring basis.

Related Parties

Related Parties - The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

Income Taxes

Stock-based Compensation

Restricted Stock Units (“RSUs”)

Restricted Stock Units (“RSUs”) - Our RSUs vest over two or four years from the date of grant. The fair value of RSUs is the market price of our common stock at the date of grant.

Performance Units (“PUs”)

Performance Units (“PUs”) - The PUs vest based on our performance against predefined share price targets and the achievement of Positive Interim, Clinical Data as defined by the Board.

Loss Per Common Share

Research and Development Costs

Segments Reporting

Segments Reporting

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Equity (Details - Performance units activity) - Performance Units [Member] - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Non-vested at beginning	19	19
Weighted-average grant date fair value non-vested at beginning	$ 14,581.58	$ 14,581.58
PUs granted	0	0
Weighted average grant date fair value granted	$ 0	$ 0
PUs vested	(6)	0
Weighted average grant date fair value vested	$ 25,050.00	$ 0
PUs forfeited	(8)	0
Weighted average grant date fair value forfeited	$ 9,750.00	$ 0
Non-vested at ending	5	19
Weighted-average grant date fair value non-vested at ending	$ 9,750.00	$ 14,581.58

Income Taxes (Details - Effective income tax rate reconciliation) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income tax benefit computed at the statutory rate	$ 3,120,000	$ 3,959,000
True-ups and non-deductible expenses	(585,000)	118,000
Change in valuation allowance	(2,535,000)	(4,077,000)
Provision for income taxes	$ 0	$ 0

Income Taxes (Details Narrative)	12 Months Ended
Income Taxes (Details Narrative)	Dec. 31, 2024 USD ($)
Income Tax Disclosure [Abstract]
Operating loss carry forward	$ 37,727,000
Operating loss carry forward, description	Approximately $200,000 of the net operating loss carryforward will begin to expire in 2037.

Note Payable (Details Narrative) - USD ($)	Nov. 28, 2024	Nov. 28, 2023	Dec. 31, 2024	Dec. 31, 2023
Short-Term Debt [Line Items]
Note payable balance			$ 326,072	$ 300,806
November 2024 Note [Member]
Short-Term Debt [Line Items]
Short-term note payable	$ 326,072
Interest rate	9.24%
Maturity date	Oct. 08, 2025
Note payable balance			326,072
November 2023 Note [Member]
Short-Term Debt [Line Items]
Short-term note payable		$ 329,571
Interest rate		9.74%
Maturity date		Oct. 08, 2024
Note payable balance			$ 0	$ 300,806

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Cash in excess of FDIC		$ 6,211,378
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	59,579	1,732
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	114	6
Unvested Performance Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	5	19
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	270	157

Income Taxes (Details - Deferred tax assets) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Deferred income tax assets
Net operating losses	$ 7,923,000	$ 6,672,000
Stock-based compensation	999,000	873,000
Capitalized 174 expenses	6,659,000	5,420,000
Deferred income tax liability
Prepaid expenses	(279,000)	(198,000)
Valuation allowance	(15,302,000)	(12,767,000)
Net deferred income tax assets	$ 0	$ 0

Nature of Business (Details Narrative)	Nov. 26, 2024	Jun. 04, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reverse stock split	1-for-50	1-for-50

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	1,413,556	2,486
Common stock, shares outstanding	1,413,556	2,486

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Pay vs Performance Disclosure - USD ($)	12 Months Ended
Pay vs Performance Disclosure - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (14,857,801)	$ (18,851,226)

Summary of Significant Accounting Policies (Details - Estimated useful lives)	12 Months Ended
	Dec. 31, 2024
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Shorter of estimated useful lives or the term of the lease
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful Life	3 years
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful Life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Estimated useful Life	7 years

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true